CA2320302A1 - Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery - Google Patents

Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery Download PDF

Info

Publication number
CA2320302A1
CA2320302A1 CA002320302A CA2320302A CA2320302A1 CA 2320302 A1 CA2320302 A1 CA 2320302A1 CA 002320302 A CA002320302 A CA 002320302A CA 2320302 A CA2320302 A CA 2320302A CA 2320302 A1 CA2320302 A1 CA 2320302A1
Authority
CA
Canada
Prior art keywords
vector
histamine
fgf
protein
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320302A
Other languages
English (en)
French (fr)
Inventor
H. Kirk Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320302A1 publication Critical patent/CA2320302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
CA002320302A 1998-02-11 1999-02-09 Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery Abandoned CA2320302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2177398A 1998-02-11 1998-02-11
US09/021,773 1998-02-11
PCT/US1999/002702 WO1999040945A2 (en) 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Publications (1)

Publication Number Publication Date
CA2320302A1 true CA2320302A1 (en) 1999-08-19

Family

ID=21806073

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320302A Abandoned CA2320302A1 (en) 1998-02-11 1999-02-09 Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery

Country Status (11)

Country Link
EP (2) EP1053025A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002502885A (cg-RX-API-DMAC7.html)
KR (1) KR20010015915A (cg-RX-API-DMAC7.html)
CN (2) CN100350979C (cg-RX-API-DMAC7.html)
AU (1) AU2663799A (cg-RX-API-DMAC7.html)
CA (1) CA2320302A1 (cg-RX-API-DMAC7.html)
EA (1) EA019099B1 (cg-RX-API-DMAC7.html)
IL (1) IL137765A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ545047A (cg-RX-API-DMAC7.html)
WO (1) WO1999040945A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA991102B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
CA2412847A1 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
EP2236153A3 (en) 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Compositons and methods for treating cardiac conditions
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
JP5290290B2 (ja) 2007-07-18 2013-09-18 シルク・ロード・メディカル・インコーポレイテッド 頚動脈血流の逆流を確立する方法およびシステム
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2014160887A2 (en) * 2013-03-28 2014-10-02 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
WO2019089385A1 (en) 2017-11-02 2019-05-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5869230A (en) * 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
WO1999017807A1 (en) * 1997-10-08 1999-04-15 Cobra Therapeutics Ltd. Use of a vasoactive compound in the enhancement of gene delivery
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods

Also Published As

Publication number Publication date
WO1999040945A2 (en) 1999-08-19
ZA991102B (en) 2000-03-31
IL137765A0 (en) 2001-10-31
WO1999040945A3 (en) 1999-09-30
EP1695719A1 (en) 2006-08-30
CN101186928A (zh) 2008-05-28
CN1301181A (zh) 2001-06-27
CN100350979C (zh) 2007-11-28
JP2002502885A (ja) 2002-01-29
EA200000828A1 (ru) 2001-02-26
AU2663799A (en) 1999-08-30
EA019099B1 (ru) 2014-01-30
KR20010015915A (ko) 2001-02-26
EP1053025A2 (en) 2000-11-22
NZ545047A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
US5792453A (en) Gene transfer-mediated angiogenesis therapy
US6174871B1 (en) Gene therapies for enhancing cardiac function
AU767662B2 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
AU784392B2 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP1695719A1 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
AU2006200170B2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU706050C (en) Gene transfer-mediated angiogenesis therapy
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU4754199A (en) Gene transfer-mediated angiogenesis therapy
AU2006235836A1 (en) Gene transfer-mediated angiogenesis therapy
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160623